Elena Elimova

Sep 15, 2023 | brnw.ch | Markus Moehler |Steven Blum |Elena Elimova |David Cella

Gastric/gastroesophageal junction cancer (GC/GEJC) and esophageal adenocarcinoma (EAC) are among the leading causes of global cancer-related mortality.1 Strong similarities in molecular profiles between GC/GEJC and EAC suggest that these cancers could be considered a single disease entity.2,3 Chemotherapy, the standard first-line treatment for patients with unresectable advanced or metastatic human epidermal growth factor receptor 2 (HER2)–negative GC/GEJC, has been associated with poor...